Updates from the Annual Session18 January 2000Update in RheumatologyRichard Wernick, MD and Stephen M. Campbell, MDRichard Wernick, MDFrom Providence Portland Medical Center and Veterans Affairs Medical Center, Portland, Oregon.Search for more papers by this author and Stephen M. Campbell, MDFrom Providence Portland Medical Center and Veterans Affairs Medical Center, Portland, Oregon.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-2-200001180-00007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Our search of recent general medical and rheumatology journals for this Update focused on studies that used reasonably valid methods and yielded practical and clinically relevant results. We selected key articles in four subject areas: nonsteroidal anti-inflammatory drugs (NSAIDs), particularly their ability to inhibit cyclooxygenase-2 (COX-2) selectively; vaccination against Lyme disease; new biological treatments for rheumatoid arthritis; and prevention and management of back pain.Nonsteroidal Anti-Inflammatory DrugsOne of the two isoforms of COX, known as COX-1, is expressed in most tissues and promotes formation of the prostaglandins needed for normal physiology. Inhibiting COX-1 suppresses the formation of beneficial prostaglandins ...References1. Lipsky PE, Abramson SB, Crofford L, Dubois RN, Simon LS, van de Putte LB. The classification of cyclooxygenase inhibitors. J Rheumatol. 1998;25:2298-303. MedlineGoogle Scholar2. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al . Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-9. LinkGoogle Scholar3. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1998;41:16-25. CrossrefMedlineGoogle Scholar4. Geis SG, Hubbard R, Callison D, Yu S, Zhao W. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis [Abstract]. Arthritis Rheum. 1998;41:S364. Google Scholar5. Geis SG, Stead H, Morant S, Naudin R, Hubbard R. Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis [Abstract]. Arthritis Rheum. 1998;41:S316. Google Scholar6. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, et al . Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975-9. CrossrefMedlineGoogle Scholar7. Marshall B. NSAIDs and Helicobacter pylori: therapeutic options. Lancet. 1998;352:1001-3. CrossrefMedlineGoogle Scholar8. Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy A, et al . Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science. 1998;281:703-6. CrossrefMedlineGoogle Scholar9. Advisory Committee on Immunization Practices. Recommendations for the use of Lyme disease vaccine. MMWR Morb Mortal Wkly Rep. 1999;48 RR-7 1-17, 21-5. MedlineGoogle Scholar10. . New drugs for rheumatoid arthritis. Med Lett Drugs Ther. 1998;40:110-2. MedlineGoogle Scholar11. van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain. A systematic review of randomized, controlled trials of the most common interventions. Spine. 1997;22:2128-56. CrossrefMedlineGoogle Scholar12. Skargren EI, Oberg BE, Carlsson PG, Gade M. Cost and effectiveness analysis of chiropractic and physiotherapy treatment for low-back and neck pain. Six-month follow-up. Spine. 1997;22:2167-77. CrossrefMedlineGoogle Scholar13. van den Hoogen HJ, Koes BW, van Eijk JT, Bouter M, Deville W. On the course of low back pain in general practice: a one year follow up study. Ann Rheum Dis. 1998;57:13-9. CrossrefMedlineGoogle Scholar14. van Poppel MN, Koes BW, van der Ploeg T, Smid T, Bouter LM. Lumbar supports and education for the prevention of low-back pain in industry: a randomized, controlled trial. JAMA. 1998;279:1789-94. CrossrefMedlineGoogle Scholar15. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder G. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40:1873-8. CrossrefMedlineGoogle Scholar16. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;125:961-8. LinkGoogle Scholar17. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al . Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337:382-7. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Richard Wernick, MD; Stephen M. Campbell, MDAffiliations: From Providence Portland Medical Center and Veterans Affairs Medical Center, Portland, Oregon.Corresponding Author: For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, [email protected]acponline.org.Current Author Addresses: Dr. Wernick: Providence Portland Medical Center, 4805 NE Glisan, Portland, OR 97213.Dr. Campbell: Veterans Affairs Medical Center, 3710 SW U.S. Veterans Hospital Road, Portland, OR 97202. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImmunomodulatory and Anti-inflammatory Effect of p-Coumaric Acid, a Common Dietary Polyphenol on Experimental Inflammation in RatsIn vitro modulation of inflammatory cytokine and IgG levels by extracts of Perna canaliculusAnakinraPain management in polycystic kidney diseaseFrom symptomatic treatments to causative therapy?Anti-TNF agents for rheumatoid arthritis 18 January 2000Volume 132, Issue 2Page: 125-133KeywordsCyclooxygenase 2DrugsLower back painLyme diseaseMethotrexateNSAIDsProstaglandinsRheumatoid arthritisUlcersVaccines ePublished: 15 August 2000 Issue Published: 18 January 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Wernick et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: